Clinical Trials

OMNY Health Bolsters C-Suite, Hires New Chief Commercial Officer

The Leader in Democratizing Data Access Brings Aboard the Former Group Vice President of Life Sciences at Komodo Health

OMNY Health, the leading healthcare ecosystem known for facilitating compliant cross-industry data sharing, today announced the first expansion of its c-suite since 2021. Ivy Weng, MD, former Group Vice President of Life Sciences at Komodo Health, will join OMNclY Health as its first Chief Commercial Officer following its most significant growth milestone yet: one billion patient encounters, which impact the care outcomes of millions of patients.

Weng will oversee OMNY Health’s commercial operations as it looks to scale, drive revenue growth, and elevate its market presence in life sciences, AI, medical devices, and clinical research organizations. ​​Weng’s extensive background in the life sciences sector includes leading enterprise multi-year software sale deals exceeding $50 million with the top 20 pharmaceutical companies. Her experience across areas such as commercial analytics, medical affairs, market access, RWE/HEOR, clinical development, and R&D will be instrumental in advancing OMNY Health’s development and implementation of commercial strategy.

“I’m excited to join OMNY Health and continue driving our mission of enhancing healthcare data connectivity and accessibility. OMNY’s platform uniquely connects providers with life sciences companies, creating a virtuous cycle that directly benefits both clinicians and patient outcomes,” said Weng. “OMNY is building the richest tapestry of representative patient encounters—and we’re just getting started.”

OMNY Health’s work with AI and life sciences partners, including QuantHealth and ArisGlobal, expedites drug development through simulated clinical trials and utilizes real-world evidence to predict clinical trial outcomes, drug efficacy, and patient responses. OMNY Health’s data also addresses disparities in pharma by closing significant demographic information gaps in drug discovery and development.

“We have merely scratched the surface of OMNY Health’s impact with our milestone of one billion patient encounters,” said Mitesh Rao, MD, Founder and CEO of OMNY Health. “Although we’ve seen tremendous growth since 2017, there remains a vast amount of work ahead in democratizing access to data and empowering life sciences, health systems, AI companies, and more to drive healthcare innovation. Appointing Ivy Weng to lead our commercial division was a clear decision—her leadership will be instrumental in advancing OMNY Health’s mission to enable deeper clinical research and impact the lives of millions more as we continue to expand.”

This news comes on the heels of the company’s GLP-1 Data Network, which supplies life sciences and health system partners, as well as its AI-driven health tech partners, with additional knowledge of GLP-1 use, related social determinants of health (SDOH) and patient demographics to better inform generative AI tools, researchers, and clinicians. To learn more about how OMNY Health transforms lives and drives patient care by connecting providers and life sciences companies through data, visit https://omnyhealth.com/.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

Related posts

WCG releases Clinical Research Trends & Insights 2024 Report

PR Newswire

Parexel wins 2023 North American Customer Value Leadership Award

PR Newswire

Veeva Introduces Vault Basics for Biotechs

PR Newswire